2023-06-28 12:08:19
Dong-A ST and Neurobo Pharmaceuticals, a US drug development subsidiary, presented the weight loss effect of the anti-obesity drug ‘DA-1726’ at the 83rd American Diabetes Association (ADA) held at the San Diego Convention Center from the 23rd to the 26th. The results were announced on the 28th.
The American Diabetes Association is the world’s most prestigious diabetes-related international conference, and Dong-A ST and Neurobo Pharmaceuticals presented preclinical study data of DA-1726 through poster and oral presentations.
DA-1726 is a new drug candidate under development as an obesity treatment of the Oxyntomodulin analogue class. It simultaneously acts on the GLP-1 receptor and the Glucagon receptor to suppress appetite, promote insulin secretion, and increase basal metabolic rate in the periphery, ultimately leading to weight loss and blood sugar control.
According to preclinical study data, DA-1726 showed excellent weight loss effects in obese animal models, despite similar food intake to the GLP-1 analogue Semaglutide (semaglutide), and the GLP-1, GIP dual agonist Tirzepatide (tirzepatide) A similar weight loss effect was confirmed despite a higher food intake. Metabolic indicators such as glucose, triglyceride, and total cholesterol (T-CHO) showed improvement compared to Tirzepatide.
In addition, it has been confirmed that DA-1726 has a mechanism that induces weight loss by promoting energy consumption by increasing the expression of Ucp1 and Ppargc1a, which are involved in increasing basal metabolic rate in white fat, with a glucagon-like action that increases energy metabolism. .
In a comparative preclinical study of Cotadutide (Cotadutide) and DA-1726, another oxyntomodulin analogue, DA-1726 showed an effect in weight loss compared to Cotadutide, and reduced plasma triglyceride and total cholesterol (T-CHO). showed up In the homeostasis model evaluation (HOMA-IR), improvement in insulin and insulin resistance was confirmed, and it is expected that the indication will be expanded to diabetes in the future.
An official from Neurobo Pharmaceuticals said, “According to the preclinical results of DA-1726, effective weight loss and blood sugar control are expected. said.
Correspondent Changhyun Lee of Hellotti |
1687982132
#DongA #Neurobo #Pharmaceuticals #announces #weight #loss #effect #antiobesity #drug #ADA
